U.S. Markets closed

Awakn Life Sciences Corp. (AWKN.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
2.2500-0.0300 (-1.32%)
At close: 3:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2800
Bid2.2500 x N/A
Ask2.2800 x N/A
Day's Range2.2400 - 2.2800
52 Week Range1.5000 - 2.5000
Avg. Volume18,636
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London

    This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College Lond

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector

    Key Takeaways: Akerna Corp. Acquires 365 Cannabis For $17M, Seeks To Create Most Comprehensive ERP System In Cannabis Industry. HEXO Corp. Achieves Carbon Neutrality. Fire & Flower Holdings Corp. Announces its Financial and Operational Results for the Fiscal Second Quarter Ended July 31, 2021. This was followed by Reports of Completed Acquisitions of PotGuide and […] The post Weekly Roundup on the Cannabis Sector appeared first on Market Exclusive.

  • Newsfile

    Awakn Life Sciences to Present at the Oppenheimer and Maxim Group September Investor Conferences

    Toronto, Ontario--(Newsfile Corp. - September 20, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in the following upcoming September investor conferences. Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Monday, September 20th - Thursday, September 23rdPresen